These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 24816068)
21. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Yang M; Nonaka D Mod Pathol; 2010 May; 23(5):654-61. PubMed ID: 20173733 [TBL] [Abstract][Full Text] [Related]
22. Mesotheliomas with small cell features: report of eight cases. Ordóñez NG Mod Pathol; 2012 May; 25(5):689-98. PubMed ID: 22222641 [TBL] [Abstract][Full Text] [Related]
23. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Pan CC; Chen PC; Chou TY; Chiang H Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817 [TBL] [Abstract][Full Text] [Related]
24. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Comin CE; Saieva C; Messerini L Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535 [TBL] [Abstract][Full Text] [Related]
25. Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Ordóñez NG Am J Clin Pathol; 2013 May; 139(5):611-9. PubMed ID: 23596113 [TBL] [Abstract][Full Text] [Related]
26. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Amatya VJ; Kushitani K; Kai Y; Suzuki R; Miyata Y; Okada M; Takeshima Y Mod Pathol; 2018 May; 31(5):809-815. PubMed ID: 29327712 [TBL] [Abstract][Full Text] [Related]
27. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Padgett DM; Cathro HP; Wick MR; Mills SE Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779 [TBL] [Abstract][Full Text] [Related]
28. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. Lew M; Pang JC; Jing X; Fields KL; Roh MH Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236 [TBL] [Abstract][Full Text] [Related]
29. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Ordóñez NG Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794 [TBL] [Abstract][Full Text] [Related]
30. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma. Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868 [TBL] [Abstract][Full Text] [Related]
31. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Ordóñez NG Hum Pathol; 2013 Jan; 44(1):1-19. PubMed ID: 22963903 [TBL] [Abstract][Full Text] [Related]
32. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265 [TBL] [Abstract][Full Text] [Related]
33. Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases. Churg A; Naso JR Histopathology; 2023 Feb; 82(3):385-392. PubMed ID: 36008876 [TBL] [Abstract][Full Text] [Related]
34. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. Abutaily AS; Addis BJ; Roche WR J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995 [TBL] [Abstract][Full Text] [Related]
35. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Attanoos RL; Webb R; Dojcinov SD; Gibbs AR Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489 [TBL] [Abstract][Full Text] [Related]
36. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Ordóñez NG Hum Pathol; 2007 Jan; 38(1):1-16. PubMed ID: 17056092 [TBL] [Abstract][Full Text] [Related]
37. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Miettinen M; Limon J; Niezabitowski A; Lasota J Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772 [TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Foster MR; Johnson JE; Olson SJ; Allred DC Arch Pathol Lab Med; 2001 Oct; 125(10):1316-20. PubMed ID: 11570906 [TBL] [Abstract][Full Text] [Related]
39. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4. Naso JR; Churg A Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920 [TBL] [Abstract][Full Text] [Related]
40. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Amatya VJ; Takeshima Y; Kohno H; Kushitani K; Yamada T; Morimoto C; Inai K Histopathology; 2009 Jul; 55(1):10-9. PubMed ID: 19614762 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]